Introduction
============

Colorectal cancer (CRC) is one of the most common cancer types globally ([@b1-ol-0-0-10388]). In the United States, New Zealand and France the incidence and mortality rates of CRC have exhibited a downward trend, resulting from early screening, improved therapy and preventive lifestyle choices ([@b2-ol-0-0-10388]). The primary preventive measure for CRC is a healthy lifestyle, including the maintenance of a healthy weight, exercise, reduction of meat and alcohol consumption, and avoidance of smoking ([@b1-ol-0-0-10388]). It is widely accepted that surgical resection is the principal therapy option at the early stages of CRC, which is defined as invasion and lymph node metastasis only occurring locally ([@b3-ol-0-0-10388]). In addition, adjuvant chemotherapy is an essential treatment for numerous patients with resectable CRC ([@b4-ol-0-0-10388]).

Platelets are involved in multiple mechanisms of cancer development and metastasis ([@b5-ol-0-0-10388]). Platelet-associated indicators assessed by routine blood examination include platelet count (PLT), mean platelet volume (MPV), platelet distribution width (PDW) and plateletcrit (PCT). MPV reflects the average size, stimulation and production rate of platelets. Pro-inflammatory and pro-thrombotic conditions are closely associated with MPV ([@b6-ol-0-0-10388],[@b7-ol-0-0-10388]). PCT is calculated as the MPV multiplied by the PLT. It has been identified that an elevated PCT is associated with coronary artery disease and an increased risk of venous thrombosis ([@b8-ol-0-0-10388],[@b9-ol-0-0-10388]). The PDW is one of the platelet volume indicators, reflecting the average change in platelet volume ([@b10-ol-0-0-10388]). Therefore, platelet-associated indicators may be used as inflammatory markers for CRC, in addition to their use in inflammatory, thromboembolic and cardiovascular diseases.

In the present study, the hypothesis that platelet-associated indices may provide useful prognostic information was investigated in patients with resectable CRC.

Materials and methods
=====================

### Subjects and inclusion criteria

The present study was conducted as a retrospective investigation of patients with resectable CRC that had been referred to the First Affiliated Hospital of Soochow University (Jiangsu, China) between June 2006 and July 2016. The Medical Ethics Committees of the First Affiliated Hospital of Soochow University granted approval for the present study, and written informed consent to participate was obtained from patients at the beginning of the study. The clinical and pathological records of all participating patients were reviewed periodically.

In total, 153 patients with resectable CRC were recruited. All cases were confirmed by surgery and pathology. All patients originally received six cycles of XELOX treatment, a standard adjuvant chemotherapy including oxaliplatin administered intravenously at a dose of 130 mg/m^2^ on day 1, and capecitabine (850--1,250 mg/m^2^) twice a day for 2 weeks, followed by a 1-week rest. Patient characteristics are detailed in [Table I](#tI-ol-0-0-10388){ref-type="table"}. The median age of the patients was 56 years (range, 27--85 years); 70 patients were male and 83 were female. Cancer stage was determined using the Tumor-Node-Metastasis (TNM) classification according to the recommendations of the American Joint Committee on Cancer (AJCC) ([@b11-ol-0-0-10388]). Prognostic analyses were performed in regard to overall survival (OS).

### Blood samples

Pre-surgery blood samples were collected up to 1 week before surgery. Post-surgery blood samples were regarded as pre-chemotherapy samples and were collected 3 weeks after surgery. Post-chemotherapy samples were collected after 3 months of standard chemotherapy in order to eliminate the impact of treatment on platelet-associated indicators. Peripheral venous blood (5--7 ml) was collected into sterile EDTA tubes. All blood samples were fasted and obtained between 6:30 and 7:30 a.m. in order to standardize the known impact of circulating hormones (circadian rhythm) on the number and subtype distribution of various white blood cell indices ([@b12-ol-0-0-10388]). Hematological parameters were analyzed up to 30 min after collection, using a hematology analyzer (Sysmex XE-2100; Sysmex Corporation). PLT, PCT, MPV and PDW blood levels are recorded in [Table I](#tI-ol-0-0-10388){ref-type="table"}. The patients were divided into two groups according to the median value of PLT, PCT, MPV or PDW. The post-/pre-treatment ratios were defined as the rate of pre- and post-treatment blood parameter values.

### Computed tomography (CT) evaluation

CT scans were performed every 2 months for response assessment and evaluated according to the criteria of the Response Evaluation Criteria in Solid Tumors 1.1 ([@b13-ol-0-0-10388]).

### Follow-up

Patient survival time was recorded from the date of chemotherapy until death or the last clinical evaluation. Prognostic analyses were performed in relation to patient OS time. OS was defined as the time from diagnosis to that of death from any cause.

### Statistical analysis

All statistical analyses were performed using SPSS 19.0 software (IBM Corp.). For analysis of survival data, Kaplan-Meier curves were constructed and statistical analysis was performed using the log-rank test. The associations between blood-parameter status and clinicopathological features were determined using the χ^2^ test. The associations between alterations in the status of platelet-associated indicators and surgery or chemotherapy were assessed using a Student\'s t-test. The multivariate logistic regression model was employed to identify the independent risk factors associated with resectable CRC. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Pre-treatment PLT, PCT, MPV and PDW values do not correlate with the outcome of patients with resectable CRC

Kaplan-Meier plots were used to determine the effects of pre-treatment PLT, PCT, MPV and PDW status on OS ([Fig. 1](#f1-ol-0-0-10388){ref-type="fig"}). The patients were divided into two groups according to the median value of PLT (low PLT, ≤211.575×10^9^/l, or high PLT, \>211.575×10^9^/l), PCT (low PCT, ≤0.225 l/l, or high PCT, \>0.225 l/l), MPV (low MPV, ≤10.400 fl, or high MPV, \>10.400 fl) or PDW (low PDW, ≤15.485%, or high PDW, \>15.485%). The mean OS of the high PLT group was 63 months (range, 53.392--72.608), while that of the low PLT group was 56 months (range, 49.312--62.688; P=0.956). The mean OS was 58 months (range, 52.731--63.269) in the high PCT group and 64 months (range, 51.806--76.194) in the low PCT group (P=0.496). The mean OS of the high MPV group was 58 months (range, 53.728--62.272), while that of the low MPV group was 68 months (range, 46.025--89.975; P=0.107). The mean OS was 52 months (range, 44.465--59.535) in the high PDW group and 63 months (range, 58.623--67.377) in the low PDW group (P=0.300). These results demonstrated that pre-treatment levels of PLT, PCT, MPV or PDW had no effects on the OS of patients with resectable CRC.

Surgery significantly decreases MPV, but has no impact on PLT, PCT or PDW. The effects of surgery on the values for PLT, PCT, MPV and PDW are presented in [Fig. 2](#f2-ol-0-0-10388){ref-type="fig"}. The median PLT value was 216.000×10^9^/l \[95% confidence interval (CI), 201.030--230.970×10^9^/l\] before surgery, and 207.000×10^9^/l (95% CI, 194.210--219.800×10^9^/l) after surgery (P=0.278). The median PCT value was 0.200 l/l (95% CI, 0.190--0.220 l/l) before surgery, and 0.190 L/L (95% CI, 0.170--0.220 l/l) after surgery (P=0.407). The median MPV value was 10.000 fl (95% CI, 9.680--10.400 fl) before surgery, and 9.900 fl (95% CI, 9.300--10.198 fl) after surgery (P\<0.001). The median PDW value was 15.600% (95% CI, 15.040--15.900%) before surgery, and 15.300% (95% CI, 14.760--15.700%) after surgery (P=0.344). Therefore, surgery significantly decreased the MPV value, but had no significant impact on the PLT, PCT and PDW values of patients with resectable CRC.

### Adjuvant chemotherapy significantly decreases PLT and PCT, and increases MPV, but has no effect on PDW

The effects of adjuvant chemotherapy on the values for PLT, PCT, MPV and PDW are shown in [Fig. 3](#f3-ol-0-0-10388){ref-type="fig"}. The median PLT value was 207.000×10^9^/l (95% CI, 194.210--219.800×10^9^/l) before, and 157.000×10^9^/l (95% CI, 149.160--164.840×10^9^/l) after adjuvant chemotherapy (P\<0.001). The median PCT value was 0.190 l/l (95% CI, 0.170--0.220 l/l) before, and 0.170 l/l (95% CI, 0.160--0.180 l/l) following adjuvant chemotherapy (P\<0.001). The median MPV value was 9.900 fl (95% CI, 9.300--10.198 fl) before, and 10.500 fl (95% CI, 10.200--10.800 fl) following adjuvant chemotherapy (P\<0.001). The median PDW value was 15.300% (95% CI, 14.760--15.700%) before adjuvant chemotherapy, and 14.300% (95% CI, 13.200--15.000%) after adjuvant chemotherapy (P=0.093). Adjuvant chemotherapy significantly decreased the PLT and PCT values, but increased the MPV value of patients with resectable CRC. There was no significant impact on the PDW value.

### A whole course of treatment significantly decreases PLT, PCT and PDW, but has no effect on MPV

The impact of the whole course of treatment (surgery and adjuvant chemotherapy) on the values for PLT, PCT, MPV and PDW are displayed in [Fig. 4](#f4-ol-0-0-10388){ref-type="fig"}. The median PLT value was 216.000×10^9^/l (95% CI, 201.030--230.970×10^9^/l) before treatment and 157.000×10^9^/l (95% CI, 149.160--164.840×10^9^/l) after treatment (P\<0.001). The PCT median value was 0.200 l/l (95% CI, 0.190--0.220 l/l) before treatment and 0.170 l/l (95% CI, 0.160--0.180 l/l) after treatment (P\<0.001). The median MPV value was 10.000 fl (95% CI, 9.680--10.400 fl) before treatment and 10.500 fl (95% CI, 10.200--10.800 fl) after treatment (P=0.322). The median PDW value was 15.600% (95% CI, 15.040--15.900%) before treatment, and 14.300% (95% CI, 13.200--15.000%) after treatment (P=0.012). Treatment with surgery and adjuvant chemotherapy significantly decreased the PLT, PCT and PDW values, but had no obvious effect on the MPV value of patients with resectable CRC.

### Changes in MPV following a whole course of treatment predict the outcomes of patients with resectable CRC

Kaplan-Meier plots were used to determine the effect of changes in PLT, PCT, MPV and PDW status on OS ([Fig. 5](#f5-ol-0-0-10388){ref-type="fig"}). The mean OS of patients whose MPV decreased following a whole course of treatment (surgery and adjuvant chemotherapy) was 75 months (range, 65.918--85.211), while that of patients whose MPV did not decrease was 97 months (range, 90.599--103.210). Significant differences were identified for OS between these two groups (P=0.005). The mean OS of patients whose PLT level decreased following a whole course of treatment was 92 months (range, 85.875--97.804), while that of patients whose PLT did not decrease was 62 months (range, 46.703--77.742; P=0.096). The mean OS of patients whose PCT level decreased following a whole course of treatment was 92 months (range, 85.409--98.433), while that of the non-decreased group was 78 months (rang, 66.979--90.514; P=0.192). The mean OS of patients whose PDW level decreased following a whole course of treatment was 77 months (range, 71.466--83.015), while those where PDW did not decrease was 88 months (range, 79.668--97.597; P=0.744). Thus, the patients whose MPV level increased following surgery and adjuvant chemotherapy had increased survival ratios. However, changes in PLT, PCT and PDW had no significant effect on OS.

### Univariate and multivariate analyses of prognostic factors in patients with resectable CRC

Univariate analyses demonstrated that sex \[female; hazard ratio (HR), 2.911; 95% confidence interval (CI), 1.413--5.998; P=0.004), tumor size (\>5 cm; HR 2.613; 95% CI 1.351--5.054; P=0.004), lymphonodus metastasis (N2; HR 2.197; 95% CI 1.153--4.187; P=0.017), AJCC stage (III; HR 2.408; 95% CI 1.103--5.254; P=0.027) and decreased post/pre-treatment MPV ratio (HR 2.430; 95% CI 1.274--4.636; P=0.007) were significant risk factors for poor prognosis ([Table II](#tII-ol-0-0-10388){ref-type="table"}). In multivariate analysis, sex (female; HR 3.236; 95% CI 1.553--6.745; P=0.002), tumor size (\>5 cm; HR 2.058; 95% CI 1.007--4.203; P=0.048) and decreased post/pre-treatment MPV ratio (HR 2.621; 95% CI 1.329--5.131; P=0.005) were found to be independently associated with poor survival.

Discussion
==========

Platelets, derived from megakaryocytes, have a crucial role in a variety of physiological and pathological processes, including hemostasis, wound healing, inflammatory responses and thrombosis. Previous studies have confirmed that a high PLT, which is associated with tumorigenesis, metastasis and angiogenesis, is a common phenomenon in patients with solid cancer types ([@b14-ol-0-0-10388],[@b15-ol-0-0-10388]). Meta-analyses have suggested that a high PLT may have diagnostic and prognostic value in various types of cancer, including CRC ([@b16-ol-0-0-10388],[@b17-ol-0-0-10388]). Platelet activation is involved in progressive tumor growth and metastasis via the release of cytokines, chemokines and the expression of numerous adhesion receptors ([@b18-ol-0-0-10388],[@b19-ol-0-0-10388]). Cancer cell-derived interleukin (IL-)6 is a trigger for high, tumor-induced PLT in several types of cancer ([@b20-ol-0-0-10388],[@b21-ol-0-0-10388]). By protecting circulating tumor cells from immune-surveillance, platelets contribute to metastasis ([@b14-ol-0-0-10388]). In addition, the obstructions formed by platelets and tumor cells in the microcirculation facilitate the extravasation of tumor cells to metastatic sites. In the present study, surgery combined with adjuvant chemotherapy significantly decreased the PLT of patients with CRC. Chemotherapy was likely the primary cause of this downregulation, since surgery had no effect on PLT status. However, the post/pre-treatment ratio of PLT, which was based on changes in individual PLTs, had no apparent association with OS.

Platelet-associated indicators are closely associated with the activation and function of platelets. MPV reflects early platelet activation ([@b6-ol-0-0-10388]--[@b10-ol-0-0-10388],[@b14-ol-0-0-10388]--[@b22-ol-0-0-10388]) and PCT, obtained by multiplying the PLT and the MPV, reflects the percentage of the blood volume occupied by platelets. The PDW has been one of the most commonly used markers to indicate platelet activity. According to previous studies, there may be a correlation between platelet-associated indicators and the prognosis of patients with cancer ([@b23-ol-0-0-10388],[@b24-ol-0-0-10388]). The PCT differs depending on the stage, histological type and metastatic status of various types of cancer. For instance, the PCT is higher in patients with epithelial ovarian or endometrial cancer compared with that in healthy controls ([@b25-ol-0-0-10388],[@b26-ol-0-0-10388]). PCT was also reported to be positively correlated with common causes of mortality, including venous thrombosis and tumor metastasis, in patients with CRC ([@b8-ol-0-0-10388],[@b27-ol-0-0-10388],[@b28-ol-0-0-10388]). Although surgery and adjuvant chemotherapy significantly reduced PCT in the present study, the post/pre-treatment ratio of PCT was not associated with OS.

The implication of the MPV is controversial at present. Certain studies have indicated that MPV in patients with cancer was higher compared with that in normal controls ([@b29-ol-0-0-10388],[@b30-ol-0-0-10388]). In addition, other studies have reported a positive correlation between high MPV and advanced cancer stage ([@b24-ol-0-0-10388],[@b31-ol-0-0-10388]). However, several studies have indicated the opposite, stating that a low MPV was associated with unfavorable prognoses in non-small cell lung cancer (NSCLC) ([@b32-ol-0-0-10388],[@b33-ol-0-0-10388]). Kumagai *et al* ([@b33-ol-0-0-10388]) determined that in patients with resectable NSCLC, an MPV of \<8.50 fl was an independent predictive indicator for shorter disease-free survival and OS. In addition, Tuncel *et al* ([@b34-ol-0-0-10388]) demonstrated that the MPV was significantly higher in patients with metastatic CRC (mCRC) compared with that in patients with non-mCRC, and that the benefits of bevacizumab on progression-free survival were significantly greater in patients with low MPV, compared with those with high MPV status. Furthermore, in a study by Li *et al* ([@b35-ol-0-0-10388]), patients with a low MPV (≤8.6 fl) had a significantly improved OS compared with those with a high MPV (\>8.6 fl). Multivariate analysis revealed that high MPV was an independent risk factor affecting OS in patients with resectable CRC. In the present study, surgery increased MPV, while chemotherapy decreased it, leading to an MPV that was unchanged (compared with baseline) following treatment with both surgery and adjuvant chemotherapy. Furthermore, based on individual MPV values, subjects whose MPV\'s were not decreased had better outcomes. Univariate and multivariate analyses demonstrated that a decreased post/pre-treatment MPV ratio was a significant and independent risk factor associated with poor prognosis. Therefore, an unchanged MPV following treatment may indicate a favorable prognostic index in resectable CRC.

The association between decreased MPV and poor prognosis may be due to a number of variables. The key to explaining this decrease may be the association between blood coagulation and cancer in general. A study has demonstrated that tumor necrosis factor-α, IL-1β, vascular endothelial growth factor and basic fibroblast growth factor released from various cells stimulated the formation of vascular endothelial thrombi, and enhanced the destruction of larger-sized platelets, resulting in a decreased MPV in the circulating platelets ([@b36-ol-0-0-10388]). Another study suggested that increased thrombotic activity in patients with metastatic colon cancer led to a decrease in the MPV, which was in most cases considered to correlate with poor survival ([@b37-ol-0-0-10388]).

PDW, another platelet index, has been reported to be a diagnostic and prognostic factor for cancer ([@b38-ol-0-0-10388]). Oncel *et al* ([@b10-ol-0-0-10388]) suggested that the PDW was significantly higher in patients with lung cancer compared with that in the control group. Ma *et al* ([@b25-ol-0-0-10388]) identified that the PDW was higher in the epithelial ovarian cancer group compared with that in the benign tumor and healthy control groups. Hirahara *et al* ([@b39-ol-0-0-10388]) focused on PDW and cancer-specific survival in patients with esophageal cancer. Due to a small proportion of patients with an elevated PDW, it was not possible to assess the statistical association between PDW and prognostic factors. In a recent retrospective study by Song *et al* ([@b40-ol-0-0-10388]), univariate analysis revealed that an elevated PDW was an independent risk factor for recurrence-free survival and OS in patients with non-mCRC. In the present study, it was identified that surgery combined with adjuvant chemotherapy significantly decreased PDW. However, the post/pre-treatment ratio of PDW had no significant impact on OS.

In conclusion, the present study indicated that an increased MPV following a whole course of treatment was associated with improved OS in patients with resectable CRC, and that a low post-/pre-treatment MPV ratio was an independent negative prognostic factor for OS. Of note, the present study had certain limitations. It was a retrospective study with a small sample size, involving only 153 patients. Patients with systemic diseases, including hypertension, diabetes, rheumatic disease and infection were excluded in order to eliminate the impact of these conditions on platelet-associated indicators. In spite of the small sample size, the results of the present study were representative to a certain extent. A multi-center study with a larger sample population will be performed in the future.
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![Pre-treatment PLT, PCT, MPV and PDW values are not associated with the outcome of patients with resectable colorectal cancer. The OS according to (A) PLT, (B) PCT, (C) MPV and (D) PDW. OS, overall survival; PLT, platelet count; PCT, plateletcrit; MPV, mean platelet volume; PDW, platelet distribution width.](ol-18-01-0571-g00){#f1-ol-0-0-10388}

![Surgery significantly decreases the MPV value in patients with resectable colorectal cancer. Surgery had no influence on (A) PLT or (B) PCT. (C) Surgery significantly decreased the MPV of patients with colorectal cancer. (D) Surgery had no influence on the PDW. PLT, platelet count; PCT, plateletcrit; MPV, mean platelet volume; PDW, platelet distribution width.](ol-18-01-0571-g01){#f2-ol-0-0-10388}

![Adjuvant chemotherapy significantly decreases the values of PLT and PCT, and increases MPV in patients with resectable CRC. Chemotherapy significantly decreased the (A) PLT and (B) PCT, and significantly increased the (C) MPV of patients with CRC. (D) Chemotherapy had no influence on the PDW of patients with CRC. CRC, colorectal cancer; PLT, platelet count; PCT, plateletcrit; MPV, mean platelet volume; PDW, platelet distribution width.](ol-18-01-0571-g02){#f3-ol-0-0-10388}

![PLT, PCT and PDW values are significantly decreased in patients with CRC following a whole course of treatment. A whole course of treatment (surgery combined with adjuvant chemotherapy) significantly decreased the (A) PLT and (B) PCT of patients with CRC. Combined treatment had no influence on the (C) MPV, but significantly decreased the (D) PDW of patients with CRC. CRC, colorectal cancer; PLT, platelet count; PCT, plateletcrit; MPV, mean platelet volume; PDW, platelet distribution width.](ol-18-01-0571-g03){#f4-ol-0-0-10388}

![Alterations in MPV following a whole course of treatment predict the outcomes of patients with resectable CRC. The OS of patients with CRC according to changes in (A) PLT, (B) PCT, (C) MPV and (D) PDW. CRC, colorectal cancer; PLT, platelet count; PCT, plateletcrit; MPV, mean platelet volume; PDW, platelet distribution width.](ol-18-01-0571-g04){#f5-ol-0-0-10388}

###### 

Clinicopathological features of patients with colorectal cancer.

                            Platelet count   Plateletcrit   Mean platelet volume   Platelet distribution width                                                                            
  ------------------- ----- ---------------- -------------- ---------------------- ----------------------------- ---- ----- ------- ------- ----- ---- ------- ------- ---- ----- ------- -------
  Sex                 153                                                                                                                                                                 
    Male              70    45               25             10.058                 0.002                         42   28    3.616   0.057   35    35   0.006   0.941   36   34    0.038   0.845
    Female            83    32               51                                                                  37   46                    42    41                   44   39            
  Age, years          153                                                                                                                                                                 
    ≤56               81    38               43             0.802                  0.370                         39   42    0.837   0.360   34    47   4.802   0.028   46   35    1.399   0.237
    \>56              72    39               33                                                                  40   32                    43    29                   34   38            
  Tumor size, cm      153                                                                                                                                                                 
    ≤5                86    46               40             0.785                  0.376                         45   41    0.038   0.846   44    42   0.055   0.815   42   44    0.937   0.333
    \>5               67    31               36                                                                  34   33                    33    34                   38   29            
  Depth of invasion   153                                                                                                                                                                 
    T1, T2            17    10                 7            0.552                  0.457                         10     7   0.396   0.529     5   12   3.347   0.067   10     7   0.327   0.567
    T3, T4            136   67               69                                                                  69   67                    72    64                   70   66            
  Lymphonodus         153                                                                                                                                                                 
  Metastasis                                                                                                                                                                              
    N0, N1            111   54               57             0.456                  0.500                         53   58    2.445   0.118   55    56   0.098   0.755   62   49    2.064   0.151
    N2                42    23               19                                                                  26   16                    22    20                   18   24            
  AJCC stage          153                                                                                                                                                                 
    I, II             56    25               31             1.142                  0.285                         25   31    1.729   0.189   22    34   4.307   0.038   32   24    0.835   0.361
    III               97    52               45                                                                  54   43                    55    42                   48   49            

AJCC, American Joint Committee on Cancer.

###### 

Univariate and multivariate logistic regression analysis of risk factors for resectable colorectal cancer.

                                     Overall survival                                      
  ---------------------------------- ---------------------- ------- ---------------------- -------
  Sex                                                                                      
    Female or male                   2.911 (1.413--5.998)   0.004   3.236 (1.553--6.745)   0.002
  Age                                                                                      
    \>56 or ≤56 years                1.003 (0.974--1.034)   0.825   --                     --
  Tumor size, cm                                                                           
    \>5 or ≤5                        2.613 (1.351--5.054)   0.004   2.058 (1.007--4.203)   0.048
  Depth of invasion                                                                        
    T3-4 or T1-2                     2.591 (0.624--10.77)   0.190   --                     --
  Lymphonodus, metastasis                                                                  
    N2 or N0-1                       2.197 (1.153--4.187)   0.017   2.070 (0.967--4.429)   0.061
  AJCC stage                                                                               
    III or I--II                     2.408 (1.103--5.254)   0.027   1.440 (0.588--3.529)   0.425
  Pre-treatment PLT                                                                        
    ≤211.575 or \> 211.575×10^9^/l   1.018 (0.539--1.924)   0.956   --                     --
  Pre-treatment PCT                                                                        
    ≤0.225 or \>0.225 l/l            1.250 (0.656--2.383)   0.498   --                     --
  Pre-treatment MPV                                                                        
    ≤10.400 or \>10.400 fl           1.709 (0.883--3.309)   0.112   --                     --
  Pre-treatment PDW                                                                        
    ≤15.485 or \>15.485%             0.714 (0.376--1.356)   0.304   --                     --
  Post-/pre-treatment PLT ratio                                                            
    \<1 or ≥1                        0.506 (0.222--1.150)   0.104   --                     --
  Post-/pre-treatment PCT ratio                                                            
    \<1 or ≥1                        0.638 (0.322--1.264)   0.197   --                     --
  Post-/pre-treatment MPV ratio                                                            
    \<1 or ≥1                        2.430 (1.274--4.636)   0.007   2.612 (1.329--5.131)   0.005
  Post-/pre-treatment PDW ratio                                                            
    \<1 or ≥1                        0.893 (0.472--1.688)   0.727   --                     --

OR, odds ratio; CI confidence interval; PLT, platelet count; PCT, plateletcrit; MPV, mean platelet volume; PDW, platelet distribution width; AJCC, American Joint Committee on Cancer.
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